Table 3.
Frequency of metabolic syndrome components in Paget’s patient and control groups
| Patient, n % | Control, n % | p | |
|---|---|---|---|
| DM/BAG | 7/23, 30 | 0/30, 0 | 0.002 |
| Anti-HG Tx | 3/23, 13 | 0/30, 0 | 0.07 |
| HT | 11/23, 47 | 6/30, 20 | 0.04 |
| Anti-HT Tx | 11/23, 47 | 4/30, 13 | 0.01 |
| HL | 10/23, 43 | 19/30, 63 | 0.17 |
| Anti-HL Tx | 3/23, 13 | 1/30, 0.3 | 0.3 |
| MetS | 17/23, 73.91 | 9/30, 30 | <0.01 |
DM: diabetes mellitus; IFG: impaired fasting glucose; Anti-HG Tx: antihyperglycemic therapy; HBP: hypertension; Anti-HBP Tx: antihypertensive therapy; HL: hyperlipidemia; Anti-HL Tx: antihyperlipidemic therapy; MetS: metabolic syndrome.